![PPT - Blinding or Masking of Treatments and Other Aspects of the Trial PowerPoint Presentation - ID:2947805 PPT - Blinding or Masking of Treatments and Other Aspects of the Trial PowerPoint Presentation - ID:2947805](https://image1.slideserve.com/2947805/blinding-in-a-non-blind-study-l.jpg)
PPT - Blinding or Masking of Treatments and Other Aspects of the Trial PowerPoint Presentation - ID:2947805
![The EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases (TREAT-SVDs) trial: Study protocol for a randomised crossover trial - Anna Kopczak, Michael S Stringer, The EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases (TREAT-SVDs) trial: Study protocol for a randomised crossover trial - Anna Kopczak, Michael S Stringer,](https://journals.sagepub.com/cms/10.1177/23969873221143570/asset/images/large/10.1177_23969873221143570-fig2.jpeg)
The EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases (TREAT-SVDs) trial: Study protocol for a randomised crossover trial - Anna Kopczak, Michael S Stringer,
![Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - The Lancet Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - The Lancet](https://www.thelancet.com/cms/asset/8e2715b8-4a0b-4717-ac70-7d7ee212f889/gr1.jpg)
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - The Lancet
![Study overview. *PROBE: prospective randomized open blinded endpoint... | Download Scientific Diagram Study overview. *PROBE: prospective randomized open blinded endpoint... | Download Scientific Diagram](https://www.researchgate.net/publication/374778100/figure/fig1/AS:11431281199374182@1697576289728/Study-overview-PROBE-prospective-randomized-open-blinded-endpoint-design-1-primary_Q320.jpg)
Study overview. *PROBE: prospective randomized open blinded endpoint... | Download Scientific Diagram
![Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded- endpoint, randomised controlled trial - The Lancet Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded- endpoint, randomised controlled trial - The Lancet](https://www.thelancet.com/cms/asset/13767ca5-bec0-4a0b-bf76-a7de762bb086/gr1.jpg)
Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded- endpoint, randomised controlled trial - The Lancet
![Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial - The Lancet Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/71d9b432-eaa0-4a68-a936-27d7eff14013/gr1.gif)
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial - The Lancet
![Frontiers | Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol Frontiers | Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol](https://www.frontiersin.org/files/Articles/1248468/fcvm-10-1248468-HTML-r1/image_m/fcvm-10-1248468-g001.jpg)
Frontiers | Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/5584d24a-1666-42dc-9be9-55d76014e9f9/gr1.gif)
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology
![PDF] Subjective endpoints in clinical trials: the case for blinded independent central review | Semantic Scholar PDF] Subjective endpoints in clinical trials: the case for blinded independent central review | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9b64e5348e0e0732cebba88e8435a8b2465f45f9/2-Table1-1.png)
PDF] Subjective endpoints in clinical trials: the case for blinded independent central review | Semantic Scholar
![A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study | Semantic Scholar A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a80a8b9dcae6dce8ccd42713ad1e8fcf798c1403/4-Table2-1.png)
A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study | Semantic Scholar
![Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care ... Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care ...](https://cyberleninka.org/viewer_images/1315642/f/1.png)
Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care ...
![PDF] Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting | Semantic Scholar PDF] Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bcf01c43e4cd92f14a77bc86cd0ac0a2db6a2dc1/16-Figure1-1.png)